Event

Severe asthma is a heterogenous disease with multiple phenotypes and endotypes. To appropriately implement precision medicine in management of severe asthma, there need to be readily available biomarkers that are clinically helpful in phenotypic characterization. This session will review available and emerging biomarkers that are potentially useful and outline future research needs quoting evidence-based studies recently published.